Strong earnings, deflated by guidance cuts and margin quality
PAT surged 79%, but revenue missed management's claim by 280 basis points, and half the profit gain is inventory timing that won't repeat. The real tension: backward-integration plants are running late and guidance took a hit.
₹18.6 Cr
+79.3% YoY
50% inventory gain + 50% operations
+9.9%
Management claimed 12.78%
₹125 Cr Q4
Cut from ₹250 Cr full-year
Stallion delivered a quarter that looks strong on the headline — PAT up 79% — but unravels the moment you ask the three questions that matter: (1) Where did the profit really come from? (2) Does management's claimed revenue hold? (3) Is the margin gain permanent or timing-driven?
The reported number masks inventory timing
Q1 EBITDA margin came in at roughly 20%, up 75.85% year-on-year. On the call, management gave a direct answer to where half of that gain originated: high stock-keeping during the Gulf crisis shipping disruptions. MD Shehzad Rustamji stated explicitly, 'Part of it comes from the better planning that we had during the Gulf crisis time.' That's a one-time tailwind. The remaining 50% came from operational improvements and specialty product mix. Going forward, the MD cautioned: 'I'm not particularly sure that the same results can be repeated continually.' Translation: normalizing to ~10% PAT margin for core business, not 14.9%.
I'm not particularly sure that the same results can be repeated ever continually. Like I said, part of it comes from the better planning that we had during the Gulf crisis time.
Revenue growth fell 280 basis points short of management's claim
On the earnings call, management reported ₹124.68 Cr revenue for Q1, implying 12.78% year-on-year growth. The delivered result filed with BSE: ₹121.4 Cr, a 9.9% rise. The gap of ₹3.28 Cr (2.6%) is not enormous, but it's material enough to flag. No adjustment or clarification came in the Q&A. Against guidance of 30–35% CAGR over three years, a 9.9% organic growth quarter sets a lower foundation.
Revenue ₹124.68 Cr (12.78% YoY growth)
₹121.4 Cr actual (9.9% YoY)
Overstated by 280 bps
EBITDA margin 20% sustainable; margins will improve continually
MD admits 50% from one-time inventory gain; future quarters to moderate
Overstated; quality questioned
R32 plant to deliver ₹250 Cr in FY27
Reduced to ₹125 Cr (Q4 only, December ramp instead of October)
Cut 50% due to funding delay
Helium facility (Khalapur) will ramp 5→12→24 containers annually
Only 20% utilization (240 MT of 1,200 MT capacity) targeted in FY28
Supported; ramp slower than implied
What changed on this call
R32 plant FY27 contribution: ₹250 Cr → ₹125 Cr (Q4 only). Delay from October to December = 2-month slip costing ₹125 Cr in FY27 impact.
Mambattu (HFO blending) timeline: Originally August 2026 → now year-end FY27. Scope expanded (5-tank → 12-tank), shared team with R32, monsoon delays in Andhra Pradesh.
Capital structure: MD pivoted from 'strictly no dilution' to 'may need equity + debt' for HFO plant CAPEX (₹350–400 Cr) and working capital ramp.
30–35% CAGR guidance: Reaffirmed as 'intact' despite Q1 missing growth target (9.9% vs 12.78%). Math hinges on three-plant ramp to >₹1,100 Cr by FY28.
Margin guidance: Kept as 'improve 3–4% over medium term' (vague). MD explicitly hedged repeatable margins.
The bull case vs. the bear case
The honest read: Stallion is executing a genuine backward-integration bet — moving from specialty trading into manufacturing. The plants are real, the timelines are improving (9-month delivery vs. 24-month industry norm), and the markets (helium, R32) have structural tailwinds. But Q1 exposed two cracks: (1) Management's operational claims didn't match the delivered financials (revenue miss, margin quality questioned), and (2) guidance is already showing strain (R32 cut 50%, Mambattu slipped 5 months). The next 2–3 quarters are make-or-break for three concurrent ramps. If any slip, margin moderation becomes a waterfall. If all three hit, the ₹1,100 Cr + 15% PAT target is credible. Right now it's 50–50.
Ranked risks
Multi-plant execution cascade failure
HighR32, Mambattu, HFO plant all critical path. R32 already 2 mo delayed; Mambattu 5 mo delayed. If one slips further, concurrent ramp collapses. Three plants need coordinated supply chains, shared team allocation. Execution risk is >50%.
Margin quality and normalizing pressure
HighQ1 PAT margin 14.9% is not repeatable; 50% from inventory timing per MD. Core business normalizing to ~10% PAT. Q2–Q4 expected to moderate as inventory gain fades. Street models may be baking in Q1 margins; disappointment risk high.
R32 government quota uncertainty
HighCompany assumes 10,000 MT quota; not yet declared. Competitors also bidding. If quota < capacity, revenue/margin targets miss. MD acknowledged 'till government doesn't declare it everyone is hopeful.'
R32 pricing pressure and capacity overhang
Medium70–90k tons India capacity incoming vs. 20k demand (4x overhang). Pricing down to ₹800/kg from ₹900 peak. Guidance assumes ₹550/kg worst-case, but further compression possible. Swing plant dynamics (can make 125, 124a) add unpredictability.
Capital structure shift and dilution timing
MediumMD moved from 'no dilution' to 'may need equity + debt' for HFO CAPEX (₹350–400 Cr). No blueprint finalized yet. Equity raise timing and quantum unknown; risk of dilution when growth narrative is questioned.
Helium supply geopolitical dependency
MediumDependent on Middle East (Sharjah Oxygen) + Qatar Gas. Houthi blockade / Gulf tensions could disrupt. Swapping mechanism mitigates but not fully protective. 20% utilization target in FY28 (vs. 1,200 MT capacity) signals supply constraint risk.
Revenue and guidance credibility damage
MediumQ1 revenue miss (9.9% vs 12.78% claimed), R32 guidance cut 50%, Mambattu delayed 5 mo. Prior FY27 PAT guidance ₹100–110 Cr; Q1 run-rate ~₹75 Cr. Credibility dented; street will be more skeptical of guidance going forward.
How the street is positioned
Post-result price action: The stock fell 5.18% on day 1 and 11.04% by day 3 after the result announcement. The initial move faded decisively — suggesting the street parsed the margin quality issue and guidance cuts the same way. Price action is the market's verdict: reported profit beats look hollow when margin sustainability is questioned and capex guidance is slashed.
Valuation and drawdown context: At ₹225.95, the stock is down 19.01% from its all-time high of ₹279, but well above its 52-week low of ₹98.95 (+128.35% from the low). It trades below the SMA20 (₹249.99) and SMA50 (₹217.62), but above the SMA200 (₹175.07). RSI is neutral at 42.2. The stock is not in free-fall, but it's correcting from its peak. The drawdown is meaningful but not panic-driven — investors are repricing the risk of execution delays and margin moderation, not walking away entirely.
FII and DII flows: Institutional interest is cooling. Q1 FY27 shows FII at 0.83% (down 0.95 percentage points QoQ) and DII at 1.53% (down 2.51 percentage points QoQ). In Q4 FY26, FII was 1.78% and DII 4.04%. Both are in retreat — a red flag when a stock is in a critical growth phase. Promoter holding steady at 47.80% offers some insulation, but reduced institutional conviction heading into the plant ramp is not a positive signal.
Insider and block activity: Recent bulk/block deals (July 2026) show Junomoneta FinSol alternating buy/sell at ₹205–205.15 (casual algo activity, no signal). March 2026 saw Neomile Growth Fund buy 35 lakh shares at ₹108.30 and sell 32.58 lakh at the same price (likely rebalancing). No promoter/insider selling near the highs, which is a modest positive — no one with inside information is bailing. But the lack of aggressive buying from insiders is also telling.
What to watch next
1 · Khalapur helium plant Q2 commissioning (Sep-Oct FY27)
The first proof point that multi-plant execution is real. Expect ~₹15 Cr revenue contribution in H2 FY27. If on-time, credibility gains; if slips, investor confidence in Q4 R32 timeline erodes.
2 · Q2/Q3 PAT margin trajectory (normalizing from inventory boost)
The acid test of earnings quality. Core PAT should stabilize near 10% as inventory timing fades. If margins hold above 13%, execution narrative improves. If they drop below 10%, guidance for ₹100–110 Cr FY27 PAT is at risk.
3 · R32 plant ramp-up milestone (December 2026) and Q4 revenue contribution
The biggest single catalyst. December commissioning is already delayed 2 months from October. If hits, ₹125 Cr Q4 revenue validates the backward-integration thesis and keeps FY28 >₹1,100 Cr target credible. Any further slip cascades to Mambattu and damages three-plant ramp confidence.
The single number to track
Watch normalized PAT margin (ex inventory timing) for Q2–Q3. If it stabilizes at 10–12%, the 30–35% CAGR thesis holds and the stock is a Hold into the plant ramp. If it compresses below 9%, FY27 PAT guidance (₹100–110 Cr) is in jeopardy and re-rating is justified. Right now, Stallion is a Hold — the fundamentals are interesting but execution risk is elevated, and the street's post-result repricing is warranted. Conviction returns when two of three plants hit their timelines.
Stallion is in the middle of a genuine step-change: three specialty manufacturing plants ramping into FY28 to double revenue and unlock operating leverage. The opportunity is real. But Q1 showed that operational execution ≠ reported financials, margin sustainability is in question, and guidance is already bending under execution delays. The stock is repricing that gap — not a verdict, but a reasonable caution. The next two quarters will resolve the debate. Watch the margin normalize and the first two plants clear their timelines. Until then, this is a story stock, not a conviction buy.
Strong quarter masking execution delays; margin pullback expected
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
R32 contribution guidance reduced from ₹250 Cr to ₹125 Cr (50% cut). Margin sustainability questioned by MD himself. Revenue growth claimed 12.78% vs actual 9.9%.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered 79% PAT growth but revenue growth (9.9% YoY) fell short of management's claim (12.78%), and margins are half one-time inventory gains management expects to moderate. 30-35% CAGR guidance held intact long-term, but R32 plant FY27 contribution slashed 50% to ₹125 Cr due to December delay. Multi-plant ramp targeting >₹1,100 Cr by FY28 is structurally sound but execution risk is high, funding assumptions have shifted to permit dilution, and near-term (Q2-Q4 FY27) margins expected to compress as inventory boost fades.
₹124.68 Cr
Revenue · +12.78% YoY₹18.57 Cr
Reported PAT · +79.15% YoYExpanding
Margins · vs guidance: OverstatedDid the claims hold up?
Revenue growth 12.78% YoY; delivered result shows 9.9%
OVERSTATEDActual revenue ₹121.4 Cr (9.9% YoY growth), call claimed ₹124.68 Cr (12.78%)
50% of margin gain from operational improvement, 50% from inventory timing
METMD stated 50:50 split; acknowledged gains unlikely to repeat continually
R32 plant ₹250 Cr FY27 revenue contribution; now changed to ₹125 Cr Q4 only
MISSDelay to December end from original October timeline = 50% reduction in FY27 contribution
EBITDA margins sustainable; 'definitely improve' going forward
OVERSTATEDMD cautioned 'not sure same results can be repeated ever continually'; future quarters to moderate
Helium plant ramping 5→12→24 containers annually; full utilization in 2-3 years
METOnly 20% utilization (240 MT of 1,200 MT) expected in FY28; slow ramp acknowledged
Earnings quality
What changed since the last call
R32 plant FY27 contribution
DowngradePrior: ₹250 Cr (full year). New: ₹125 Cr (Q4 only, Dec-Mar). Delay from Oct to Dec = 2-month slip × 50% reduction in FY27 impact.
Mambattu plant timeline
DowngradePrior: August 2026. New: Year-end FY27. Reasons: scope expanded (5-tank → 12-tank structure), team shared with R32, monsoon delays in Andhra Pradesh.
Capital structure outlook
NeutralMD shifted from 'strictly no dilution' to 'may dilute equity + debt' for HFO plant and working capital ramp. Funding no longer fully internal-accrual driven.
30-35% CAGR guidance
MaintainedReaffirmed as 'intact' on call despite Q1 missing growth target (9.9% vs 12.78%). Math hinges on three-plant ramp in FY28 to >₹1,100 Cr.
Margin guidance 3-4% improvement
NeutralKept as 'over medium term' (vague). MD explicitly hedged: 'impressive margins not actual numbers at current business level'; future quarters to moderate.
The Q&A
Analysts pressed hard on margin sustainability, R32 demand visibility, and pre-contract coverage; MD held firm on no pre-selling rationale but hedged on repeatable margins. No hostile tone; management took questions directly with some deflection on proprietary strategy (AHF sourcing). Confidence intact but qualified.
Margin composition & sustainability — Disha, (unnamed firm)
Answered50:50 split between planning/logistics execution and inventory gains. Margins will improve but not at this level continually. Part of Q1 was one-time benefit from high stock-keeping.
Helium facility contribution — Disha
AnsweredYes, 12% contribution expected. PAT margin will be higher than 15% (we've said 15% but will be better).
R32 pricing & feasibility — Disha
AnsweredGuidance based on worst-case ₹550/kg realization, not peak ₹700-800. Workable even at current ₹800 pricing.
Mambattu delay rationale — Disha
PartialSame team working on both Bhilwara and Mambattu. Prioritized Bhilwara. Mambattu complements R32 anyway, delay has no material loss.
30-35% CAGR feasibility — Gaurav Shukla
AnsweredThe 30-35% is intact (reaffirmed). Three years in a row, driven by new plants and higher-value products.
EBITDA margin sustainability — Gaurav Shukla
AnsweredNo. This is a special quarter with planning and execution timing. Not sustainable at these levels. Working towards profitability.
R32 plant delay factors — Gaurav Shukla
AnsweredSeptember share-price spike killed preferential issue plan. Had to shift to rights issue. Funding delayed to February. Startup pushed from Dec to March (now Dec-end).
R32 FY27 revenue impact — Paras Chheda
AnsweredWould change a little bit. Q4 should be approximately ₹125 Cr. FY28 target of ₹500-600 Cr still holds.
EBITDA & PAT margin path — Paras Chheda
AnsweredEBITDA up 3-4% with production plants. PAT: 50% core business ~10%, 50% new (24% on R32) = averaging out. FY28: 15-17% PAT margin with 50:50 mix.
Peak revenue & margin targets — Paras Chheda
AnsweredExceeding ₹1,100 Cr revenue. Approximately 15% PAT margin minimum. (Then hedged: these are endeavors we're working towards.)
Helium supply security & pricing — Paras Chheda
AnsweredMultiple sourcing de-risking: Sharjah Oxygen partnership, swapping mechanism, alternative sources. Price: next 2-3 years outlook shortfall and higher pricing.
Working capital & funding strategy — Arindam Dutta
PartialDesire not to dilute, raise from internal accruals. But if want faster growth, capital may be needed. Internal accruals substantial but may require debt/dilution for HFO plant timing.
HFO plant timing & backward integration — Arindam Dutta
PartialHFO next. 20-year Honeywell relationship ensures we safeguard their IP. Confident we can proceed with proper regards to their interests.
R32 capacity utilization — Darshil Jhaveri
AnsweredCurrent turnover ~₹400 Cr. 30% of 400 = ₹120 Cr. Even with ₹125 Cr from R32, hits 525 (30% growth). Math works over 3 years.
Pre-sold capacity for R32 — Bhavika Singhvi
AnsweredExperienced management doesn't pre-sell without airtight contracts. Commitments lock in low prices; if prices fall, buyer walks. No value in MOUs. Before R32, imports >4,000 tons; internal needs 40-50% of production. Remaining easily sold.
AHF raw material sourcing — Bhavika Singhvi
PartialMultiple local + global manufacturers. New capacities coming by next year. By 2028, expect AHF glut. Confidential strategy in place; yes, we have AHF source planned. Multi-source approach; won't depend on single supplier.
Helium capacity ramp & market opportunity — Dhwanil Shah
AnsweredNo. 1,200 MT is capacity, not guaranteed supply. Ramp will be incremental (50, 100, 200 MT). Won't reach full in 2-3 years. FY28 targeting 20% utilization only.
HFO plant CAPEX & Mambattu revenue — Dhwanil Shah
AnsweredHFO plant CAPEX ₹350-400 Cr for 10,000 MT (5,000+5,000). Mambattu instant revenue jump ~10% (import replacement, 60% R32 + blending). Long-term: 1-2 years later, HFO blends business grows significantly.
Plant execution risk & timeline confidence — Ashish Parikh
AnsweredChemical process plant normally 24 months; Chinese won't do <18 months. We're delivering in 9 months (with 2-shift work). Even if delayed 2-4 months, it's half the industry norm. Mambattu: scope expanded (5→12 tanks), complete redesign required; monsoons in Andhra affected neighbors, not us.
Capital raising plans — Ashish Parikh
DodgedNot decided yet. Internal meetings showed sticking to no-dilution + internal accruals would delay growth significantly or push debt above prudent levels. Now open to some dilution + debt. Not finalized; discussing options.
R32 incremental vs. substitution — Preet Jain
AnsweredLast 2 years, imports dropped to negligible. Whatever we sell in R32 is incremental to current revenue. Profitability delta vs. procured product will boost overall returns elsewhere.
R32 quota & government policy risk — Preet Jain
PartialWe don't buy HF from that company, never have. Other sources already outlined + new manufacturers coming. Quotas: HF doesn't need it. R32 everyone gets quota per process. Till government declares, everyone hopeful.
R32 demand & market visibility — Preet Jain
AnsweredIndia needs 20,000 tons; coming capacity 70-90,000 tons (4x). Much from export. 2028: China GWP quota cuts 1,20,000 tons. Plants are swing plants—can make 125, 124a, etc. Not sacrosanct. Swing dynamics mean utilization fluidity, not linear.
R32 plant regulatory compliance — Pradeep Patel
DodgedRegulatory requirements underway.
Guidance
30-35% CAGR over next 3 years (FY27-FY30)
MediumReaffirmed on call as 'intact' but Q1 missed growth claim (9.9% vs 12.78%). Hinges on three-plant ramp (Khalapur, Mambattu, R32) to >₹1,100 Cr by FY28.
Khalapur: ~12% FY27 contribution (~₹15 Cr); ramp to ₹50+ Cr in FY28
HighPlant complete, Q2 online. 20% utilization FY28 (240 MT of 1,200 MT at ₹4,000/kg approx. ₹96 Cr potential, but only ~₹50 Cr expected near-term).
R32: ₹125 Cr Q4 FY27 (changed from ₹250 Cr full year); ₹500-600 Cr FY28
MediumDecember commissioning (2-month delay from Oct). Based on worst-case ₹550/kg realization. Current pricing ₹800/kg (off-peak). Quota uncertainty remains (government decision pending).
Mambattu: Year-end FY27 (from August); immediate ~10% revenue bump via import substitution
LowScope expanded, timeline slipped 5 months. Tied to R32 ramp for full effectiveness. Profitability lift more immediate than revenue.
EBITDA margins improve 3-4% over medium term
LowQ1 at ~20% EBITDA margin; MD explicitly hedged as 'special quarter' with 50% one-time inventory gain. Medium-term implies 2-3 years post-plant ramps.
Core business: ~10% PAT margin sustainable; R32: ~24% PAT margin target
MediumAnalyst validated this; 50:50 mix in FY28 = ~15-17% blended PAT margin. Depends on full R32 utilization + margin protection vs. pricing pressure.
Helium facility: 15-18% PAT margin (MD said 'will be higher' than 15% stated)
MediumHelium pricing stable at ₹4,000/kg. Margin upside if pricing holds; risk if supply shortage reduces scarcity premium.
HFO plant: ₹350-400 Cr CAPEX for 10,000 MT (5,000+5,000) capacity
MediumFinancing strategy under review (internal + debt vs. dilution). Announcement post-R32 commissioning (year-end FY27). Honeywell IP compliance required.
R32 & Mambattu CAPEX on track, no overspend; within original budget
HighMD stated 'very much in control.' R32 CAPEX borne via rights issue (Feb 2026). Mambattu scope expanded but still within planned envelope.
Risks the call surfaced
Execution & project delivery
HighBhilwara (R32), Mambattu, HFO plant all critical path. R32 already 2 months delayed; Mambattu 5 months delayed. Concurrent ramp increases risk of further slips or quality issues.
R32 quota & regulatory
HighR32 manufacturing quota not yet declared by government. Company assumes full 10,000 MT allocation; if quota < capacity, revenue/margin targets miss. Competitors also bidding.
Margin sustainability & quality
HighQ1 EBITDA gain 75.85%; 50% from inventory timing (Gulf crisis stockpiling), 50% operational. MD explicitly stated 'not sure same results can be repeated continually.' Future quarters expected to moderate significantly.
Working capital & liquidity
MediumThree simultaneous plant ramps + HFO CAPEX (₹350-400 Cr) will strain cash. MD shifted from 'no dilution' stance to 'may need equity + debt.' Exact capital plan not finalized; equity dilution extent unknown.
Helium supply chain
MediumHelium supply dependent on Middle East (Sharjah Oxygen partnership) + Qatar Gas agreement. Middle East shipping disruptions (Houthi blockade, Gulf tensions) could interrupt supply. Swapping mechanism mitigates but not 100% protective. Pricing upside if shortage persists (favorable for company) but availability risk remains.
Demand & market saturation
MediumIndia R32 demand ~20,000 tons/year; incoming capacity 70-90,000 tons (4x demand). Most plants are swing plants (can make 125, 124a, etc.). Pricing pressure likely unless export demand absorbs excess. Competitors rushing to 32 may see it become unlucrative; margin compression risk.
Honeywell IP & partnership
LowHFO is patented by Honeywell; Stallion has 20-year distribution relationship. MD says will respect IP, but HFO manufacturing planning may face constraints or require Honeywell approval. AHF (raw material) sourcing also carries latent dependency risks if supplier concentration exists.
Management
Score 6/10. Direct on operational details (plant timelines, pricing, capacity). Hedged on margin sustainability and capital plans (shifted from no-dilution to 'may dilute'). Transparent on inventory gains being 50% one-time. Deflected on confidential strategy (AHF sourcing). NDA shields on Honeywell discussions evident. Strong delivery on project timelines (9 months vs. 18-24 month industry norm) but facing delays (R32: +2 mo, Mambattu: +5 mo). Internal accruals building. CAPEX control claimed. Capital structure strategy shifted mid-year (from no-dilution to open to dilution). Track record: Prior FY27 PAT guidance ₹100-110 Cr; Q1 run-rate ~₹75 Cr (below).
1 · Q2 FY27 (Sep-Oct)
Khalapur helium plant commercialization; expect 12% revenue contribution (~₹15 Cr)
2 · Q4 FY27 (Jan-Mar)
Bhilwara R32 plant ramp-up (10,000 MT capacity); targeting ₹125 Cr revenue, 24% PAT margin
3 · Year-end FY27
Mambattu HFO blending plant operational (12-tank structure); tied to R32 completion
Multi-plant ramp targeting >₹1,100 Cr by FY28 is structurally sound but execution risk is high, funding assumptions have shifted to permit dilution, and near-term (Q2-Q4 FY27) margins expected to compress as inventory boost fades.
Stallion India Q1 FY27: standalone PAT jumps 79% YoY to ₹18.6 Cr as margins expand sharply
PAT +79.14% YoY · revenue +9.93% · margins expanding
₹121.45 Cr
+9.93% YoY
₹18.57 Cr
+79.14% YoY
14.89%
+5.5pp YoY
₹1.6
Stallion India's standalone Q1 FY27 (quarter ended June 30, 2026) revenue from operations rose 9.9% YoY and 10.4% QoQ to ₹121.45 Cr. Net profit surged 79.1% YoY (69.8% QoQ) to ₹18.57 Cr, well ahead of topline growth. EPS was ₹1.60 (basic and diluted) against ₹1.15 a year ago and ₹1.33 last quarter.
Q1 FY-2027 vs prior quarters
The gain was margin-led. Operating margin expanded to 18.15% from 12.94% a year ago and 14.86% last quarter, while net margin rose to 15.29% from 9.37% YoY. Combined cost of materials consumed and inventory changes fell to ~76.3% of revenue from ~79.5% YoY and ~79.4% QoQ — the principal driver. Other income also rose to ₹3.23 Cr from ₹0.74 Cr YoY on interest from unutilised IPO proceeds parked in fixed deposits (note 5); stripping that out, pre-tax profit still grew ~64% YoY, so the improvement is largely operational rather than a one-off boost.
The stock went into the print at ₹254, up 24% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
Management projects a revenue CAGR of 30-35% over the next three years, driven by backward integration, specialty product expansion, and new facilities coming online. Margin improvements of 3-4% are also expected. The company aims for INR 3,000 crore revenue and INR 500 crore PAT by 2030, supported by continuous expans
No analyst consensus for this specific print could be confirmed via web search — a pre-results preview (Univest) flagged stabilising realisations as the key swing factor but carried no numeric revenue/PAT estimate, so street comparison is unknown. Against management's own May-2026 framework — a 30-35% three-year revenue CAGR, 3-4 points of margin improvement, and a FY27 PAT target of ₹100-110 Cr — the quarter is mixed: revenue growth of 9.9% YoY trails the guided CAGR pace, but the margin gain (OPM +5.2 points YoY) already exceeds the full multi-year magnitude guided. Annualising Q1 PAT (~₹74 Cr) trails the ₹100-110 Cr FY27 target's low end, though continued margin expansion could close the gap. No separate management press release or commentary accompanied this filing.
W1
FY27 PAT guidance of ₹100-110 Cr implies ~₹25-27.5 Cr/quarter average; Q1's ₹18.57 Cr annualises to ~₹74 Cr — watch whether OPM (18.15% this quarter) keeps expanding to close the gap
W2
Deployment of the remaining ~₹10.17 Cr IPO proceeds toward the Mambattu (Andhra Pradesh) refrigerant facility and its completion timeline
W3
Revenue trajectory vs management's guided 30-35% three-year CAGR — Q1's 9.9% YoY growth trails that pace; watch for acceleration as backward integration and new facilities ramp
Only a standalone statement is filed (company states single business segment, no subsidiaries referenced); other income rose to ₹3.23 Cr (vs ₹0.74 Cr YoY) largely from interest on unutilised IPO proceeds parked in fixed deposits (note 5); Mar-31-2026 comparative column is a balancing figure per note 4; auditor issued an unmodified limited-review opinion.